Targeting mTOR for cancer therapy
H Hua, Q Kong, H Zhang, J Wang, T Luo… - Journal of hematology & …, 2019 - Springer
Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival,
metabolism, and immunity. mTOR is usually assembled into several complexes such as …
metabolism, and immunity. mTOR is usually assembled into several complexes such as …
Modeling neoplastic disease with spheroids and organoids
Cancer is a complex disease in which both genetic defects and microenvironmental
components contribute to the development, progression, and metastasization of disease …
components contribute to the development, progression, and metastasization of disease …
Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways
Oncolytic viruses (OVs) represent a new class of multi-modal immunotherapies for cancer,
with OV-elicited antitumor immunity being key to their overall therapeutic efficacy. Currently …
with OV-elicited antitumor immunity being key to their overall therapeutic efficacy. Currently …
Patient-derived organoids in precision medicine: drug screening, organoid-on-a-chip and living organoid biobank
Z Zhou, L Cong, X Cong - Frontiers in Oncology, 2021 - frontiersin.org
Organoids are in vitro self-assembling, organ-like, three-dimensional cellular structures that
stably retain key characteristics of the respective organs. Organoids can be generated from …
stably retain key characteristics of the respective organs. Organoids can be generated from …
Promising applications of tumor spheroids and organoids for personalized medicine
Simple Summary Presently, the investigation of the tumor is carried out using different
models. One of the promising areas is the creation of 3D tumor models, such as spheroids …
models. One of the promising areas is the creation of 3D tumor models, such as spheroids …
An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity
In breast cancer, genetic heterogeneity, the lack of actionable targets and immune evasion
all contribute to the limited clinical response rates to immune checkpoint blockade therapy …
all contribute to the limited clinical response rates to immune checkpoint blockade therapy …
Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy
J Qu, FS Kalyani, L Liu, T Cheng… - Cancer …, 2021 - Wiley Online Library
Patient‐derived cancer cells (PDCs) and patient‐derived xenografts (PDXs) are often used
as tumor models, but have many shortcomings. PDCs not only lack diversity in terms of cell …
as tumor models, but have many shortcomings. PDCs not only lack diversity in terms of cell …
Role of human mesenchymal stem cells in regenerative therapy
Mesenchymal stem cells (MSCs) are multipotent cells which can proliferate and replace
dead cells in the body. MSCs also secrete immunomodulatory molecules, creating a …
dead cells in the body. MSCs also secrete immunomodulatory molecules, creating a …
Cancer models in preclinical research: A chronicle review of advancement in effective cancer research
H Sajjad, S Imtiaz, T Noor, YH Siddiqui… - Animal Models and …, 2021 - Wiley Online Library
Cancer is a major stress for public well‐being and is the most dreadful disease. The models
used in the discovery of cancer treatment are continuously changing and extending toward …
used in the discovery of cancer treatment are continuously changing and extending toward …
Current perspectives on nasopharyngeal carcinoma
Abstract Of the~ 129,079 new cases of nasopharyngeal carcinoma (NPC) and 72,987
associated deaths estimated for 2018, the majority will be geographically localized to South …
associated deaths estimated for 2018, the majority will be geographically localized to South …